GKTX.PA - Genkyotex SA

Paris - Paris Delayed Price. Currency in EUR
3.7400
-0.0450 (-1.19%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close3.7850
Open3.7500
BidN/A x N/A
AskN/A x N/A
Day's Range3.6500 - 3.7500
52 Week Range3.3500 - 17.0000
Volume6,950
Avg. Volume8,726
Market Cap29.641M
Beta (3Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-1.5000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Genkyotex Announces First Half 2019 Results

    Genkyotex (Euronext Paris & Brussels: FR00013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces its consolidated financial results for the six months ended June 30, 2019, prepared in accordance with IFRS. 2019 half-year condensed consolidated financial statements were subject to a limited review by the Company’s statutory auditors. A summary of 2019 half-year condensed consolidated financial statements is included in this press release, and the 2019 half-year financial report is available in the Investors section of Genkyotex’s website (in French).

  • The Genkyotex (EPA:GKTX) Share Price Is Down 77% So Some Shareholders Are Rather Upset
    Simply Wall St.

    The Genkyotex (EPA:GKTX) Share Price Is Down 77% So Some Shareholders Are Rather Upset

    As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long...

  • GlobeNewswire

    Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that it agreed with Yorkville Advisors Global, a U.S.-based investment manager (“Yorkville” or the “Investor”), on a 12-month extension of the conversion period for its remaining €1.6 million convertible notes held by Yorkville. This has been achieved by Genkyotex buying-back from Yorkville on August 19, 2019 its remaining €1.6 million convertible notes due August 20, 2019, and simultaneously issuing to Yorkville new convertible notes equivalent to the remaining existing convertible notes and due August 20, 2020.

  • GlobeNewswire

    Genkyotex Announces Positive Post-Hoc Analysis of PBC Phase 2 Trial and Reports Cash Position at June 30, 2019

    ARCHAMPS, France, July 25, 2019 (GLOBE NEWSWIRE) --  Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today positive post-hoc analysis of PBC phase 2 trial. As previously reported, setanaxib achieved clinically meaningful reductions in liver stiffness, statistically significant reduction in gamma glutamyl transpeptidase (GGT) (p

  • GlobeNewswire

    Genkyotex Conference Call for Post-Hoc Analysis of Setanaxib (GKT831) PBC Ph2 Trial and Business Update

    ARCHAMPS, France, July 24, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, will hold a conference call on July 25, 2019 at 2pm CEST, following publication of the second quarter financial results. The call will be hosted by Elias Papatheodorou, CEO of Genkyotex, Philippe Wiesel, Chief Medical Officer of Genkyotex and Alexandre Grassin, VP Finance & Administration. Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets.

  • GlobeNewswire

    The WHO Recognizes NOX Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831

    ARCHAMPS, France, July 22, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced that the World Health Organization (WHO) has recommended setanaxib as the international nonproprietary name (INN) for GKT831. The new stem "naxib" approved by WHO refers to NADPH oxidase inhibitors, and formally establishes a new therapeutic class under the WHO INN system.

  • GlobeNewswire

    Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

    ARCHAMPS, France, July 17, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, announced today that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application allowing the initiation of a Phase 2 trial of the Company`s lead product candidate, GKT831, in patients with idiopathic pulmonary fibrosis (IPF). This will be the third Phase 2 clinical trial of GKT831 in a fibrotic disease, adding lung fibrosis to liver fibrosis and kidney fibrosis as potential clinical indications for this compound.

  • GlobeNewswire

    Genkyotex's GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model

    Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), the leading biopharmaceutical company in NOX therapies, today announced the publication of data in Clinics and Research in Hepatology and Gastroenterology showing that its anti-fibrotic drug candidate GKT831, prevents multiple complications of portal hypertension in a preclinical model. Portal hypertension, the major complication of cirrhosis, develops when advanced liver fibrosis restricts blood flow through the liver.

  • GlobeNewswire

    Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), the leading biopharmaceutical company in NOX therapies, today announced the publication of data in Clinics and Research in Hepatology and Gastroenterology showing that its anti-fibrotic drug candidate GKT831, prevents multiple complications of portal hypertension in a preclinical model. Portal hypertension, the major complication of cirrhosis, develops when advanced liver fibrosis restricts blood flow through the liver.

  • GlobeNewswire

    Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex's Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

    Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p GKT831 400mg BID significantly improved multiple quality of life metrics important to PBC patients, ...

  • What Kind Of Share Price Volatility Should You Expect For Genkyotex SA (EPA:GKTX)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For Genkyotex SA (EPA:GKTX)?

    If you own shares in Genkyotex SA (EPA:GKTX) then it's worth thinking about how it contributes to the volatility of...

  • GlobeNewswire

    Genkyotex Invites Shareholders to Annual General Meeting on June 13, 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced it will hold its Annual General Meeting on June 13, 2019. The company hereby invites shareholders to attend the AGM, which will be held on June 13th 2019, at 10:00AM CET at Club Confair, 54 rue Laffitte, 75009 Paris, France. Elias Papatheodorou, CEO of Genkyotex, commented: "This is a very exciting time for Genkyotex as we have obtained for the first-time clinical evidence of the anti-fibrotic activity of GKT831 in our phase 2 trial in PBC.

  • GlobeNewswire

    Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis

    Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced the publication of preclinical efficacy data with GKT831 for cholestatic fibrosis.

  • GlobeNewswire

    Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients

    ARCHAMPS, France, May 02, 2019 (GLOBE NEWSWIRE) --  Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial 22% reduction in liver stiffness in PBC patients with liver fibrosis compared ...

  • GlobeNewswire

    Genkyotex Conference Call

    ARCHAMPS, France, May 01, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, will hold a conference call on ...

  • GlobeNewswire

    Genkyotex Provides Corporate Update and Reports Cash Position at March 31, 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and reported cash and cash equivalents of 7.3 million, at March 31, 2019. "We look forward to the initiation of the Phase 2 NIH funded trial in Idiopathic Pulmonary Fibrosis (IPF), which is expected in the coming months," continued Mr. Papatheodorou.  "We are excited about the broad therapeutic potential of GKT831 in multiple inflammatory / fibrotic diseases.